2. Signaling Pathways
  3. Immunology/Inflammation
  4. PSMA

PSMA

Prostate-specific membrane antigen

 
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-163196
    PSMA-IN-4
    		Inhibitor
    PSMA-IN-4 (compound 9) is a potent inhibitor of PSMA, with the IC50 value of 1.2 μM.
    PSMA-IN-4
  • HY-P5990
    Prostate Specific Antigen Substrate
    Prostate Specific Antigen Substrate is a prostate specific antigen (PSA) fluorescent substrate. Prostate Specific Antigen Substrate can be used for detect enzymatic activity of PSA.
    Prostate Specific Antigen Substrate
  • HY-149297
    PSMA-IN-1
    		Inhibitor
    PSMA-IN-1 (compound 23) is an inhibitor of PSMA with a Ki value of 2.49 nM. PSMA-IN-1 inhibits tumor growth with high selectivity and specificity in PSMA+ xenograft models. PSMA-IN-1 is a NIR probe (λEX: 620 nm; λEM: 670 nm) used for tumor disappearance. PSMA-IN-1 can be used for research on prostate cancer.
    PSMA-IN-1
  • HY-161626
    PSMA binder-3
    		Chemical
    PSMA binder-3 is a binder of PSMA.
    PSMA binder-3
  • HY-148152
    PSMA I&S
    PSMA I&S is a precursor of the 99mTc-labeled PSMA-targeting ligand.
    PSMA I&S
  • HY-162779
    CDD-3290
    		Inhibitor
    CDD-3290 (Compound 20) is a prostate-specific antigen (PSA) inhibitor with a Ki value of 216 nM. CDD-3290 also inhibits α-chymotrypsin and elastase.
    CDD-3290
  • HY-158119A
    PSMA-trillium
    PSMA-trillium is a PSMA targeting compound, consisting of a PSMA targeting molecule (PSMA binder), a Macropa chelating molecule, and a group that regulates pharmacokinetics (PK modifier). PSMA-trillium is a non-radioactive form of Actinium-225-PSMA-Trillium (BAY 3563254) with improved PSMA targeting and pharmacokinetic properties. PSMA-trillium can bind Ac through the Macropa chelating molecule, or the radioactive isotope 225Actinium. Actinium-225-PSMA-Trillium is a potent inhibitor of metastatic castration-resistant prostate cancer (mCRPC).
    PSMA-trillium
  • HY-160893
    PSMA-Val-Cit-PAB-Azide
    		99.43%
    PSMA-Val-Cit-PAB-Azide is a drug-linker conjugate for ADC. PSMA-Val-Cit-PAB-Azide contains the cleavable ADCs linker (Val-Cit-PAB) and a novel small-molecule PSMA-targeted conjugate. It contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups.
    PSMA-Val-Cit-PAB-Azide
  • HY-139670
    PSMA–DA1
    PSMA–DA1 may be a useful PSMA-targeting radiotheranostic agent.
    PSMA–DA1
  • HY-P5292
    HYNIC-iPSMA
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity.
    HYNIC-iPSMA
  • HY-149298
    PSMA-IN-2
    		Inhibitor
    PSMA-IN-2 is an inhibitor of PSMA with a Ki value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λEM = 1088 nm, λex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice.
    PSMA-IN-2
  • HY-149869
    PSMA-IN-3
    		Inhibitor
    PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC50 value of 13 nM. PSMA-IN-3 is suitable for developing an 18F-labeled radioligand for PET imaging of PSMA in prostate cancer.
    PSMA-IN-3
  • HY-114256
    EC1169
    EC1169 is a specific PSMA ligand that inhibits the growth of PSMA-positive cells.
    EC1169
  • HY-164575
    NH2-NODAGA
    NH2-NODAGA is a NODAGA-type metal chelator that can bind to radionuclides to prepare radionuclide conjugates (RDCs). NH2-NODAGA can react with diethyl squarate in 0.5M phosphate buffer (room temperature, 2 h, pH 7-7.5) to obtain NODAGA.SA. NODAGA.SA can target L-lysine urea-L-glutamate (KuE), which is a key structure of prostate-specific membrane antigen (PSMA). NODAGA.SA.KuE can bind [68]Ga and can be used for PET examination of NMRInu/nu nude mice bearing LNCaP tumors.
    NH2-NODAGA
  • HY-161699
    SDTWS01
    SDTWS01 is a novel 68Ga-labeled prostate-specific membrane antigen (PSMA) targeting tracer. The inhibition constant (Ki) of SDTWS01 for PSMA is in the nanomolar range (less than 10 nM), demonstrating high affinity for PSMA. SDTWS01 exhibits significant tumor uptake and superior PET imaging effects. SDTWS01 can be utilized for diagnostic research of prostate cancer.
    SDTWS01
Cat. No. Product Name / Synonyms Application Reactivity